Patents
The latest patent-related news relating to all sectors of the chemical and pharmaceutical industries, including infringement disputes, expiries and general patent law, from the Royal Society of Chemistry's magazine, Chemistry World
-
OpinionWeight loss drug supply races
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of drugs
-
NewsDisappointing AI judgment could have a ‘catastrophic effect’ on UK science
Warnings that loose legal definitions in case could also threaten innovation in chemistry
-
BusinessExplainer: How is the US pharmaceutical patent system being misused?
What are ‘evergreening’ and ‘thicketing’ and what is being done to reform the system and aid competition?
-
NewsLandmark intellectual property ruling could offer new opportunities for chemists working with AI
UK court’s decision that an artificial neural network can be patented could have widespread ramifications
-
NewsEuropean intellectual property system ready for gene-edited crops
Updates to New Genomic Technology regulations irrelevant to IP say experts
-
BusinessUS supreme court confirms Amgen’s cholesterol antibody patents invalid
Decision could mean patent descriptions need to be even more detailed, and hence expensive
-
BusinessPharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
-
BusinessEurope gears up for streamlined patent system
Delayed Unified Patent Court set to begin operating in April
-
NewsUS chemical industry responsible for 25% of the country’s GDP
National Academies finds chemical research has ‘outsized economic value’
-
NewsChemistry appears less often in news than biology or medicine
But chemical research has a strong presence in patents, study finds
-
-
BusinessPatent office cements priority for Crispr gene editing in cells
Nobel laureates’ failed challenge means companies may need extra patent licenses
-
-
BusinessUS supreme court ends Sandoz–Amgen biosimilar dispute
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
-
-
OpinionRewards based on priority drive unnecessary competition
The story of Crispr illustrates how a focus on patents and publications can cause good people to act in unsavoury ways
-
BusinessPatent applications listing AI as an inventor run into legal problems
Artificial intelligence is increasingly being used to find new chemical compounds and repurpose drugs, but should laws be updated to protect the intellectual property of such discoveries?
-
BusinessThis little Crispr went to market
Gene editing technology heading towards commercial reality in pharmaceuticals, food and organ transplant
-
OpinionWhen should employees share profits from inventions?
Glucose monitor inventor wins £2m payout from Unilever after claiming his work provided ’outstanding benefit’
-
NewsPatient and research groups condemn draft bill allowing human gene patenting in US
A measure floated by Congress could hinder research and access to gene tests and raise their costs